Adjuvant Treatment for Stage II Invasive Ductal Carcinoma

Introduction to Adjuvant Therapy

The National Comprehensive Cancer Network recommends adjuvant endocrine therapy plus completion of one full year of HER2-targeted therapy with trastuzumab, with the addition of pertuzumab if the patient was node-positive at initial staging, for patients achieving pathologic complete response after neoadjuvant therapy for ER+/PR+/HER2+ invasive ductal carcinoma 1, 2

Complete up to 1 year total of trastuzumab therapy, administered as a Category 1 recommendation, including any cycles administered during neoadjuvant treatment 1, 2
Add pertuzumab to trastuzumab if the patient had node-positive disease at initial staging before neoadjuvant chemotherapy, continuing both agents to complete one year of dual HER2 blockade 1, 2
Consider extended adjuvant neratinib following completion of trastuzumab-based therapy for perceived high-risk ER+/HER2+ disease, though benefits after pertuzumab exposure remain unknown 2

Initiate adjuvant endocrine therapy for all ER+ and/or PR+ tumors, administered for 5-10 years, as a Category 1 recommendation 1, 2
For postmenopausal women, aromatase inhibitors are preferred over tamoxifen based on superior efficacy in hormone receptor-positive disease 3, 4
For premenopausal women, consider ovarian function suppression plus aromatase inhibitor for higher-risk presentations, particularly those initially warranting chemotherapy 1, 4

Base radiation therapy decisions on pre-chemotherapy tumor characteristics, not on post-neoadjuvant pathology, regardless of achieving pathologic complete response 1, 3
Post-mastectomy radiation is indicated if there were 4 or more positive axillary lymph nodes at initial presentation 3

Consider adjuvant bisphosphonate therapy for 3-5 years in postmenopausal patients with high-risk node-negative or node-positive tumors for risk reduction of distant metastasis 1, 2
No additional chemotherapy is indicated after achieving pathologic complete response, as panel consensus states postoperative chemotherapy has no role if a full course of standard chemotherapy was completed preoperatively 3

Do not omit endocrine therapy even with pathologic complete response—ER+ disease requires hormonal suppression regardless of chemotherapy response 1, 2
Do not base radiation decisions on post-treatment pathology—use pre-chemotherapy clinical stage and nodal status to determine radiation fields and indications 3
Monitor cardiac function before and during HER2-targeted therapy, as both trastuzumab and pertuzumab carry cardiac toxicity risks 5

The National Comprehensive Cancer Network recommends that preoperative systemic therapy has no demonstrated disease-specific survival advantage over postoperative adjuvant chemotherapy in stage II tumors, establishing equivalence of timing 6, 7
Patients who achieve pathological complete response have substantially improved survival outcomes, with the pathological complete response itself serving as a favorable prognostic indicator 8, 9

The incorporation of trastuzumab into neoadjuvant regimens increases pathological complete response rates from 26% to 65.2% in HER2+ tumors 6, 7

The National Comprehensive Cancer Network suggests that clinical staging before treatment determines local recurrence risk, not the pathologic response, which is critical for radiation therapy decisions 10

Pathological complete response should be defined as either ypT0/isypN0 or ypT0ypN0, representing absence of residual invasive carcinoma in both breast and axillary lymph nodes 8, 9
The presence or absence of residual ductal carcinoma in situ remains somewhat contentious, but FDA-supported pooled analysis found similar event-free survival and overall survival in patients without residual invasive carcinoma regardless of presence/absence of residual DCIS 8, 9
Residual disease in axillary lymph nodes indicates worse prognosis even when there is pathological complete response in the breast, hence pathological complete response definition must include absence of disease in both sites 8, 9